Product Details
1/UN
$ *.**
In StockAdditional Information
| Product Name | Xgeva 120 mg/1.7 mL Vial |
| Active Ingredient | Denosumab (Preservative-Free) |
| Mechanism of Action | RANK ligand (RANKL) inhibitor; prevents osteoclast formation, reducing bone resorption |
| Strength | 120 mg per 1.7 mL (70 mg/mL) |
| Route of Administration | Subcutaneous (SC) |
| Common Side Effects | Fatigue, musculoskeletal pain, nausea, dermatologic reactions |
| Serious Risks | Osteonecrosis of the jaw, atypical femur fractures, severe hypocalcemia, anaphylaxis |
| Precautions | Monitor calcium, phosphorus, and magnesium levels; ensure adequate calcium and vitamin D intake |
| Monitoring Parameters | Serum calcium, phosphorus, magnesium, renal function, signs of osteonecrosis |
| Storage Conditions | Refrigerate at 2°C to 8°C (36°F to 46°F); protect from light; do not freeze or shake |
| Packaging | Single-use vial |
| Usage | Management of bone-related complications in cancer and metabolic bone diseases |
Description
Xgeva 120 mg/1.7 mL is a monoclonal antibody injection containing denosumab, a RANK ligand (RANKL) inhibitor. It is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors, the treatment of giant cell tumor of bone in adults and skeletally mature adolescents, and the management of hypercalcemia of malignancy refractory to bisphosphonate therapy.
Xgeva is administered as a subcutaneous injection at a recommended dose of 120 mg once every four weeks. Additional doses may be required for certain conditions, such as giant cell tumor of bone. Patients should receive supplemental calcium and vitamin D to reduce the risk of hypocalcemia. Common adverse reactions include fatigue, musculoskeletal pain, nausea, and dermatologic reactions.
Monitoring should include calcium, phosphorus, and magnesium levels, especially in patients with risk factors for hypocalcemia. Patients with renal impairment require close observation due to an increased risk of electrolyte disturbances. Hypersensitivity reactions, including anaphylaxis, may occur and require immediate medical intervention.
Frequently Asked Questions (FAQs)
The cost of XGEVA 120 MG/1.7 ML VIAL is $$0.00
XGEVA 120 MG/1.7 ML VIAL is manufactured by AMGEN.
You can purchase XGEVA 120 MG/1.7 ML VIAL on our website at https://supplies.pipelinemedical.com/product/detail/xgeva-120-mg-1-7-ml-vial-639474